Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&D) programs to highlight the company's...

Related Keywords

China ,Japan ,Davida Ricks ,Molly Mccully ,Kevin Hern ,Daniel Skovronsky ,Eli Lilly ,Lycia Therapeutics Inc ,Mina Therapeutics ,Boehringer Ingelheim ,Research Development ,Protomer Technologies Inc ,Regor Therapeutics Group ,Rigel Pharmaceuticals Inc ,Nektar Therapeutics ,Drug Administration ,Foghorn Therapeutics Inc ,Biosciences Inc ,Exchange Commission ,Investment Community Meeting ,Lilly Research Laboratories ,European Medicines Agency ,Securities Exchange ,Devices Agency ,Kasei Pharma Corporation ,Lilly Research ,New Drug Application ,Marketing Authorization Application ,Medical Devices Agency ,Loxo Oncology ,Financial Outlook Fueled ,New Innovative ,Anat Ashkenazi ,Therapeutics Inc ,Rigel Pharmaceuticals ,Kumquat Biosciences ,Conference Call ,Securities Act ,Securities Exchange Act ,Financial Accounting Standards Board ,Eli Lilly And Company ,